Department of Nutrition and Health, Nutritional Biochemistry Laboratory, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Department of Animal Biology, Experimental Pathology Laboratory, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Nutr Rev. 2020 Aug 1;78(8):667-687. doi: 10.1093/nutrit/nuz087.
Recent evidence suggests that modulation of the gut microbiota may help prevent colorectal cancer.
The aim of this systematic review was to investigate the role of probiotics and synbiotics in the prevention of colorectal cancer and to clarify potential mechanisms involved.
The PubMed, ScienceDirect, and LILACS databases were searched for studies conducted in humans or animal models and published up to August 15, 2018.
Clinical trials and placebo-controlled experimental studies that evaluated the effects of probiotics and synbiotics in colorectal cancer and cancer associated with inflammatory bowel disease were included. Of 247 articles identified, 31 remained after exclusion criteria were applied. A search of reference lists identified 5 additional studies, for a total of 36 included studies.
Two authors independently assessed risk of bias of included studies and extracted data. Data were pooled by type of study, ie, preclinical or clinical.
The results showed positive effects of probiotics and synbiotics in preventing colorectal cancer. The main mechanisms identified were alterations in the composition and metabolic activity of the intestinal microbiota; reduction of inflammation; induction of apoptosis and inhibition of tumor growth; modulation of immune responses and cell proliferation; enhanced function of the intestinal barrier; production of compounds with anticarcinogenic activity; and modulation of oxidative stress.
Probiotics or synbiotics may help prevent colorectal cancer, but additional studies in humans are required to better inform clinical practice.
最近的证据表明,调节肠道微生物群可能有助于预防结直肠癌。
本系统评价旨在研究益生菌和合生菌在预防结直肠癌中的作用,并阐明涉及的潜在机制。
检索了 PubMed、ScienceDirect 和 LILACS 数据库中截至 2018 年 8 月 15 日发表的人类或动物模型研究。
纳入了评估益生菌和合生菌对结直肠癌和炎症性肠病相关癌症影响的临床试验和安慰剂对照实验研究。在排除标准应用后,从 247 篇文章中筛选出 31 篇。通过查阅参考文献,又确定了 5 项额外的研究,共纳入 36 项研究。
两名作者独立评估了纳入研究的偏倚风险,并提取了数据。根据研究类型(临床前或临床)对数据进行了汇总。
结果表明益生菌和合生菌对预防结直肠癌有积极作用。确定的主要机制包括肠道微生物群组成和代谢活性的改变;炎症的减少;诱导细胞凋亡和抑制肿瘤生长;免疫反应和细胞增殖的调节;肠道屏障功能的增强;产生具有抗癌活性的化合物;以及氧化应激的调节。
益生菌或合生菌可能有助于预防结直肠癌,但需要更多的人类研究来更好地为临床实践提供信息。